The image contains an infographic summarizing a study titled "3,769 Finnish Diabetic Nephropathy (FinnDiane) Study participants with type 1 diabetes." It includes three sections: 1. **Left Section**: Describes the assessment of cystatin C and creatinine-based eGFR, and the eGFRcys/eGFRcr ratio. It lists outcomes like coronary artery disease, stroke, heart failure, and all-cause mortality, accompanied by an anatomical diagram. 2. **Middle Section**: Highlights findings that eGFRcys and the eGFRcys/eGFRcr ratio are linked with CAD, stroke, PAD, HF, and all-cause mortality in individuals with albuminuria. 3. **Right Section**: Discusses the association of lower eGFRcys and eGFRcys alone with increased risk of HF and all-cause mortality in individuals without albuminuria. It also states that the ratio was not linked with any outcomes. Includes some illustrative graphs.

A discrepancy between cystatin C- and creatinine-based eGFR identifies early risk of heart failure, peripheral artery disease, and mortality in individuals with type 1 diabetes without albuminuria.

Read here ➡️ doi.org/10.2337/dc25-2987

Das stimmt, auch ich habs bis ins Ziel nicht glauben können. Die Freude war umso größer.

Schöner, aber sehr unrealistischer Wunsch!

Berlin, March 16, 2026 – The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD), has met its primary endpoint. The results showed that finerenone reduced kidney function decline by achieving a statistically significant and clinically meaningful improvement versus placebo in addition to standard of care in the estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change in eGFR from baseline to Month 32. The eGFR slope is a validated surrogate endpoint for clinical kidney outcomes and is used as a predictive metric for the risk of kidney failure. Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone. The clinical data from FIND-CKD will be presented at an upcoming scientific conference, and Bayer plans to submit the data to health authorities to extend the indication of Kerendia™ to this patient population.

FIND CKD meets primary outcome (GFR slope) in n ~ 1500 with proteinuric non-diabetic CKD

Bayer press release:
www.bayer.com/media/en-us/...

BL data + design paper pubmed.ncbi.nlm.nih.gov/38858818/ in NDT

H/T Brendon Neuen on LinkedIn (!)

Saline Doesn’t Ruin Hyponatremia Labs (It Might Help) A study by Dr. Chienwichai highlights challenges in diagnosing hyponatremia due to undisclosed intravenous saline administration. While saline infusion does not obscure urine biochemical tests, it …

Saline Doesn’t Ruin Hyponatremia Labs (and it might help)

How many times have you been evaluating a patient in the ED and bemoaned the sneaky liter of saline they got before anyone sent some urine for analysis. Turns out it doesn't ruin the labs at all.

pbfluids.com/2026/03/sali...

Original Article | MAR 11, 2026 Finerenone in Type 1 Diabetes and Chronic Kidney Disease (FINE-ONE) Figure 1. Change in the Urinary Albumin-to-Creatinine Ratio.

In adults with type 1 diabetes and chronic kidney disease with albuminuria, the decrease in the urinary albumin-to-creatinine ratio was significantly greater with finerenone than with placebo. Full phase 3 FINE-ONE trial results: nej.md/4rTPAmu

#MedSky #EndoSky #Nephrology

Lower eGFR in type 1 diabetes doesn't appear to raise DKA risk. This encourages research into drugs like SGLTi, which may increase DKA risk but offer crucial kidney protection.

Read here ➡️ doi.org/10.2337/dc25-1955

Figure showing the putative molecular mechanisms of the liver–gut–muscle axis in metabolic dysfunction-associated steatotic liver disease and sarcopenia.

Featured in our March issue: Ming-Hua Zheng and colleagues review the connections between MASLD, sarcopenia and metabolic syndrome and discuss how care for patients affected by these diseases is evolving rdcu.be/e4fae
#EndoSky #MedSky

Wir durften als Young Diabetologists die 1. Winter School für Kolleg:innen veranstalten: Im Programm gab es praxisrelevante Workshops & Fortbildung zu medizinischer Gesprächsführung. 🤓🏔️📚💉Auch eine weitere Folge für Öglykäm wurde aufgezeichnet. 🎧 @yd-austria.bsky.social

Figure showing the effect of statin versus placebo on events listed in statin SmPCs, subdivided by component parts. Results for two outcomes with fewer than ten events are not shown in the figure, but are included in the appendix. FDR=false discovery rate. LFT=liver function test. RBC=red blood cell. RR=rate ratio. SmPC=Summary of Product Characteristics. *FDR significant at the 5% level; RR for results FDR-significant at the 5% level are indicated by black circles and RR for results not FDR-significant at the 5% level indicated by grey circles. †Excluded from FDR testing; RR for results excluded from FDR testing indicated by white circles.

Almost all side effects on statin labels not caused by statins, finds major meta-analysis; authors call for labels to be updated.

Find out more 👉 spkl.io/63324AsjHO

From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 #Diabetes Mellitus and #CKD

https://doi.org/10.1016/j.ekir.2025.09.027

#KIRReview

🎬Episode 7 of Best of #EASD2025 is live! Dr. Michael Leutner (Medical University of Vienna) shares his key highlights, focusing on the SOUL trial and new insights into #HeartFailure and peripheral artery disease in #T2D.
🎥Watch👉 youtu.be/EgoIFh2bT-M?...
#Diabetes #DiabetesResearch

Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) ca. 2026 from @kdigo.org
#Nephpearls #NephSky

👉 kdigo.org/guidelines/a...

The Entire New Yorker Archive Is Now Fully Digitized For the first time, every cover, article, and issue in the magazine’s hundred-year history can be enjoyed on newyorker.com.

This is big and a very long time coming! Your TBR pile just got 100 years longer. www.newyorker.com/news/press-r...

So wunderbar!

Now that is probably as reduced as possible 👏

Yes. This is a game changer. Beyond being able to replace AVS, it allows one to “see” the underlying pathological contributors to a large proportion of “idiopathic” hypertension. This is another piece of evidence that should make clinicians rethink the pathogenesis and treatment of hypertension

😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?

🖇️: rdcu.be/eLAde

#LiverSky @georg-semmler.bsky.social

Interesting company choice, but I'm glad its not gone entirely. Thanks for the insight!

So they didn't discontinue Bimagrumab?

Log In - pdfFiller

Paper of the Month#62

Es mehrt sich die Evidenz zur Effektivität von GLP1 RA bei Menschen mit T1D.
Dieses Mal berichten wir über eine Studie bei denen Semaglutide bei (vorwiegend adipösen) Menschen m. T1D unter Pumpen/AID Systemen eingesetzt wurde

Link zum PotM: 🖇️: www.pdffiller.com/s/Z2_qi9tBEB

Which makes it even worse one cannot attend online 😔

FINE-ONE (Finerenone in albuminuric T1DM) results should be out soon/will be presented at ASN kidney week :)

Core Curriculum by Biff F. Palmer and Deborah J. Clegg:

Mixed Acid-Base Disturbances: Core Curriculum 2025

bit.ly/Palmer25CC (FREE)

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...

New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#OpenAccess

#MedSky #EndoSky #RenalSky

Going to add this to my lecture slides.

I think I'm speaking for a lot of people here when I say it would be much appreciated if you post it on bluesky simultaneously.

Ein Held meiner Kindheit, nebst Mira Lobe, Astrid Lindgren, Janosch und dem immer noch innig geliebten Erwin Moser.

Excellent decision, easy to remember, imho. Although I'd much rather be in a Sean Connery than in a Roger Moore trial ;-)